Dr. Xinyong  Liu

Dr. Xinyong Liu

Research Director/VP of Research
Shandong University, China


Highest Degree
Ph.D. in Medicinal Chemistry from Shandong University, China

Share this Profile

Area of Interest:

Chemistry
100%
Rational Drug Design
62%
Synthesis
90%
Medicinal Chemistry
75%
Chemical Compounds
55%

Education

2004

Ph.D.

Shandong University, China

Medicinal Chemistry

Selected Publications

  1. Zhang, L., P. Zhan, X. Chen, Z. Li and Z. Xie et al., 2014. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 22: 633-642.
    CrossRef  |  

  2. Li, Z., F. Yu, L. Cui, W. Chen and S. Wang et al., 2014. Ligustrazine derivatives. Part 8: Design, synthesis and preliminary biological evaluation of novel ligustrazinyl amides as cardiovascular agents. Med. Chem., 10: 81-89.
    Direct Link  |  

  3. Zhan, P., X. Chen, D. Li, Z. Fang, E. De Clercq and X. Liu, 2013. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity and impliations for drug design. Med. Res. Rev., 33: E1-E72.
    CrossRef  |  Direct Link  |  

  4. Zhan, P. and X. Liu, 2013. Rationally designed multitarget anti-HIV agents. Curr. Med. Chem., 20: 1743-1758.

  5. Tian, Y., D. Rai, P. Zhan, C. Pannecouque and J. Balzarini et al., 2013. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA-02-13-1571). Chem. Biol. Drug Des., 82: 384-393.

  6. Sun, S.D., S.Q. Mi, J. You, J.L. Yu, S.Q. Hu and X.Y. Liu, 2013. HQSAR study and molecular design of benzimidazole derivatives as corrosion inhibitors. Acta Phys. Chim. Sin., 29: 1192-1200.
    Direct Link  |  

  7. Song, Y., Z. Fang, P. Zhan and X. Liu, 2013. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. Curr. Med. Chem., 21: 329-355.
    Direct Link  |  

  8. Song, Y., P. Zhan, Q. Zhang and X. Liu, 2013. Privileged scaffolds or promiscuous binders: A glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Des., 19: 1528-1548.
    Direct Link  |  

  9. Song, Y., P. Zhan, E. De Clercq, X. Li, D. Rai and X. Liu, 2013. Multivalent agents: A novel concept for anti-HIV drug discovery. Curr. Med. Chem., 20: 815-832.

  10. Song, Y., P. Zhan, D. Kang, X. Li and Y. Tian et al., 2013. Discovery of novel pyridaziylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. Med. Chem. Commun., 4: 810-816.
    CrossRef  |  

  11. Song, Y., P. Zhan and X. Liu, 2013. Heterocycle-thioacetic acid motif: A privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Des., 19: 7141-7154.
    Direct Link  |  

  12. Rai, D., W. Chen, Y. Tian, X. Chen and P. Zhan et al., 2013. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 21: 7398-7405.
    CrossRef  |  

  13. Liu, H., X. Wei, L. Chen, X. Liu, S. Li, X. Liu and X. Zhang, 2013. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion injury in the rat by an antioxidant action via inhibition of NADPH oxidase and iNOS expression. Pharmacology, 92: 198-206.
    CrossRef  |  

  14. Li, Z., Y. Cao, P. Zhan, C. Pannecouque, E. De Clercq and X. Liu, 2013. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Lett. Drug Des. Discovery, 10: 27-34.
    CrossRef  |  

  15. Li, Z., Y. Cao, P. Zhan, C. Pannecouque and J. Balzarini et al., 2013. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Med. Chem., 9: 968-973.
    Direct Link  |  

  16. Li, W., P. Zhan, E. De Clercq, H. Lou and X. Liu, 2013. Current drug research on PEGylation with small molecular agents. Prog. Polym. Sci., 38: 421-444.
    CrossRef  |  

  17. Li, D., P. Zhan, H. Liu, C. Pannecouque, J. Balzarini, E. De Clercq and X. Liu, 2013. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorg. Med. Chem., 21: 2128-2134.
    CrossRef  |  

  18. Kang, D., Y. Song, P. Zhan, Q. Zhang and X. Liu, 2013. Design, synthesis, and acetylcholinesterase inhibition assay of novel 9-(1-(Substituted-benzyl)piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives. J. Chem., Vol. 2013. 10.1155/2013/107302.
    CrossRef  |  

  19. Chen, X., Y. Li, S. Ding, J. Balzarini and C. Pannecouque et al., 2013. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. ChemMedChem, 8: 1117-1126.
    CrossRef  |  

  20. Chen, X., X. Liu, Q. Meng, D. Wang and H. Liu et al., 2013. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 23: 6593-6597.
    CrossRef  |  

  21. Chen, X., S. Ding, P. Zhan and X. Liu, 2013. Recent advances of diaryl ether family as HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Pharm. Des., 19: 2829-2838.
    Direct Link  |  

  22. Chen, W., P. Zhan, E. De Clercq, C. Pannecouque, J. Balzarini, X. Jiang and X. Liu et al., 2013. Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorg. Med. Chem., 21: 7091-7100.

  23. Chen, W., P. Zhan, D. Rai, B. Huang, J. Yang and X. Liu, 2013. Facile synthesis of derivatives of 1,1,3-Trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine: A new heterocyclic system. Heteroatoms Chem., 24: 495-501.
    CrossRef  |  

  24. Chen, H., G. Li, P. Zhan, X. Guo, Q. Ding, S. Wang and X. Liu, 2013. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Med. Chem. Commun., 4: 827-832.
    CrossRef  |  

  25. Zhan, P., X. Li, Z. Li, X. Chen and Y. Tian et al., 2012. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 22: 7155-7162.
    CrossRef  |  Direct Link  |  

  26. Zhan, P., W. Chen, Z. Li, X. Li and X. Chen et al., 2012. Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorg. Med. Chem., 20: 6795-6802.
    CrossRef  |  Direct Link  |  

  27. Zhan, P., L. Wang, H. Liu, X. Chen and X. Li et al., 2012. Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Arch. Pharmacal Res., 35: 975-986.
    CrossRef  |  Direct Link  |  

  28. Zhan, P., D. Li, J. Li, X. Chen and X. Liu, 2012. Benzimidazole heterocycle as a privileged scaffold in antiviral agents. Mini-Review Org. Chem., 9: 397-410.
    CrossRef  |  

  29. Zhai, L., P. Zhang, R.Y. Sun, X.Y. Liu, W.G. Liu and X.L. Guo, 2012. Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol. Rep., 63: 1469-1480.
    Direct Link  |  

  30. Tian, Y., P. Zhan, D. Rai, J. Zhang, E. De Clercq and X. Liu, 2012. Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 19: 2026-2037.
    CrossRef  |  

  31. Li, Z., P. Zhan, L. Naesens, E. Vanderlinden and A. Liu et al., 2012. Synthesis and preliminary biologic evaluation of 5-substituted-2-(4-substituted phenyl)-1,3-benzoxazoles as a novel class of influenza virus a inhibitors. Chem. Biol. Drug Des., 79: 1018-1024.
    CrossRef  |  

  32. Li, Z., F. Yu, L. Cui, P. Zhan, S. Wang and X. Liu, 2012. Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents. Med. Chem., 8: 928-933.

  33. Li, X., P. Zhan, H. Liu, D. Li and L. Wang et al., 2012. Arylazolyl(azinyl)thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorg. Med. Chem., 20: 5527-5536.
    CrossRef  |  

  34. Li, X., P. Zhan, E. De Clercq and X. Liu, 2012. The HIV-1 non-nucleoside reverse transcriptase inhibitors (Part 5): Capravirine and its analogues. Curr. Med. Chem., 19: 6138-6149.

  35. Li, W., J. Wu, P. Zhan, Y. Chang, C. Pannecouque, E. De Clercq and X. Liu, 2012. Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. Int. J. Biol. Macromol., 50: 974-980.
    CrossRef  |  

  36. Li, D., P. Zhan, E. de Clercq and X. Liu, 2012. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: Lessons from the development of seven representative paradigms. J. Med. Chem., 55: 3595-3613.
    CrossRef  |  

  37. Jiang, X., P. Zhan, X. Liu and E. De Clercq, 2012. Synthesis and Anti-HIV activity evaluation of 2-(5-(naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides derivatives. Lett. Am. J. Pharm., 31: 751-755.

  38. Deng, L., X. Guo, L. Zhai, Y. Song and H. Chen et al., 2012. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents. Chem. Biol. Drug Des., 79: 731-739.

  39. Chen, X., P. Zhan, X. Liu, Z. Cheng and C. Meng et al., 2012. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem., 20: 3856-3864.
    CrossRef  |  

  40. Chen, X., P. Zhan, C. Pannecouque, J. Balzarini, E. De Clercq and X. Liu, 2012. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur. J. Med. Chem., 51: 60-66.
    CrossRef  |  

  41. Chen, W., P. Zhan, J. Wu, Z. Li and X. Liu, 2012. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family. Curr. Pharm. Des., 18: 4165-4186.
    Direct Link  |  

  42. Chen, W., P. Zhan, E. De Clercq and X. Liu, 2012. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors. Curr. Pharm. Des., 18: 100-112.
    Direct Link  |  

  43. Zhang, J., P. Zhan, J. Wu, Z. Li and Y. Jiang et al., 2011. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 19: 4366-4376.
    CrossRef  |  PubMed  |  

  44. Zhang J., W. Ge, P. Zhan, E. De Clercq and X. Liu, 2011. Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV-1 replication. Curr. Med. Chem., 18: 2649-2654.
    CrossRef  |  PubMed  |  

  45. Zhan, P., X. Chen, X. Liu, C. Pannecouque and L. Naesens et al., 2011. Thiazolylthioacetamides as a novel class of potential antiviral agents. Antiviral Res., 90: A67-A67.

  46. Zhan, P., X. Chen, X. Li, D. Li and Y. Tian et al., 2011. Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. Eur. J. Med. Chem., 46: 5039-5045.
    CrossRef  |  PubMed  |  Direct Link  |  

  47. Zhan, P., R. Yan, X. Liu, C. Pannecouque and M. Witvrouw et al., 2011. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-2H,4H-pyrazolo[4,5-e] [1,2,4]thiadiazine derivatives. Drug Discov. Ther., 5: 279-285.
    PubMed  |  

  48. Zhan, P., D. Li, X. Chen, X. Liu, E. De Clercq, 2011. Functional roles of Azoles Motif in anti-HIV agents. Curr. Med. Chem., 18:: 29-46.
    CrossRef  |  PubMed  |  

  49. Zhan, P. and X. Liu, 2011. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A patent review (2005 - 2010). Exp. Opin. Ther. Patents, 21: 1-80.
    CrossRef  |  PubMed  |  

  50. Yu, M., X. Liu, A. Liu, G. Du, L. Naesens, E. Vanderlinden and E. De Clercq, 2011. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. Chem. Biol. Drug Des., 78: 596-602.
    CrossRef  |  PubMed  |  

  51. Yu, M., E. Fan, J. Wu and X. Liu, 2011. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 18: 2376-2385.
    CrossRef  |  PubMed  |  

  52. Song, Y.N., X.L. Guo, B.B. Zheng, X.Y. Liu, X. Dong, L.G. Yu and Y.N. Cheng, 2011. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Toxicol. Vitro., 25: 937-943.
    CrossRef  |  PubMed  |  

  53. Mingyan, Y., Z. Li, S. Liu, C. Pannecouque, E. De Clercq and X. Liu, 2011. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Chem. Med. Chem., 6: 826-833.

  54. Li, Z., P. Zhan and X. Liu, 2011. 1,3,4-Oxadiazole: A Privileged Structure in antiviral agents. Mini Rev. Med. Chem., 11: 1130-1142.
    PubMed  |  

  55. Li, W., P. Zhan, J. Wu, Y. Chang and C. Pannecouque, E. De Clercq and X. Liu, 2011. Synthesis, influence of polymer molecular weight on drug release and anti-HIV Activity of pegylated AZT conjugates. Antiviral Res., 90: A37-A37.
    Direct Link  |  

  56. Jiang, Y., X. Liu and E. De Clercq, 2011. New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle. Curr. Med. Chem., 18: 16-28.
    CrossRef  |  PubMed  |  

  57. Hu, S.Q., S.Q. Mi, X.L. Jia, C.C. Fan, S.H. Chen, J. Zhang and X.Y. Liu, 2011. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors. Chem. J. Chinese Univ., 32: 2402-2409.
    Direct Link  |  

  58. Chen, X., P. Zhan, D. Li, E. De Clercq and X. Liu, 2011. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr. Med. Chem., 18: 359-376.
    CrossRef  |  PubMed  |  

  59. Chen, H., P. Zhan and X. Liu, 2011. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. Eur. J. Med. Chem., 46: 5609-5615.
    CrossRef  |  PubMed  |  

  60. Zhan, P., Z. Li and X. Liu, 2010. Cosalane and its analogues: A unique class of anti-HIV agents. Mini-Reviews Med. Chem., 10: 966-976.
    Direct Link  |  

  61. Zhan, P., X. Liu, Z. Fang, Z. Li, C. Pannecouque and E. De Clercq, 2010. 1,2,3-thiadiazole thioacetanilides. Part 2. Synthesis and biological evaluation of a new series of 2-(4-(3,4-dichlorophenyl)-1,2,3-Thiadiazol-5-ylthio)acetamides as anti-HIV-1 inhibitors. Chem. Biodivers., 7: 1717-1726.

  62. Zhan, P., X. Liu and E. De Clercq, 2010. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Curr. Med. Chem., 17: 495-503.
    Direct Link  |  

  63. Zhan, P., X. Jiang and X. Liu, 2010. Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitors. Mini-Rev. Med. Chem., 10: 161-171.
    Direct Link  |  

  64. Zhan, P., W. Li, H. Chen and X. Liu, 2010. Targeting protein-protein interactions: A promising avenue of anti-HIV drug discovery. Curr. Med. Chem., 17: 3393-3409.
    Direct Link  |  

  65. Zhan, P., H. Liu, X. Liu, Y. Wang, C. Pannecouque, M. Witvrouw and E. De Clercq, 2010. Synthesis and anti-HIV activity evaluation of novel N1-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Med. Chem. Res., 19: 652-663.

  66. Ou, Y., X.L. Guo, L. Zhai, X.Y. Liu and Y.N. Cheng, 2010. TMPDP, a tetramethylpyrazine derivative, protects vascular endothelial cells from oxidation damage by hydrogen peroxide. Pharmazie, 65: 755-759.
    Direct Link  |  

  67. Ou, Y., X. Dong, X.Y. Liu, X.C. Cheng, Y.N. Cheng, L.G. Yu and X.L. Guo, 2010. Mechanism of tetramethylpyrazine analogue CXC195 inhibition of hydrogen peroxide-induced apoptosis in human endothelial cells. Biol. Pharm. Bull., 33: 432-438.
    Direct Link  |  

  68. Li, W., Y. Chang, P. Zhan, N. Zhang, X. Liu, C. Pannecouque and E. De Clercq, 2010. Synthesis, in vitro and in vivo release kinetics and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, zidovudine). ChemMedChem, 5: 1893-1898.
    CrossRef  |  Direct Link  |  

  69. Chen, H., X. Liu, P. Zhan and E. De Clercq, 2010. TSG101: A novel anti-HIV-1 drug target. Curr. Med. Chem., 17: 750-758.
    Direct Link  |  

  70. Zhang, J., X. Liu and E. De Clercq, 2009. Capsid (CA) protein as a novel drug target: Recent progress in the research of HIV-1 CA inhibitors. Mini-Reviews Med. Chem., 9: 510-518.
    Direct Link  |  

  71. Zhan, P., Z. Li, X. Liu and E. De Clercq, 2009. Sulfanyltriazole/tetrazoles: A promising class of HIV-1 NNRTIs. Mini-Reviews Med. Chem., 9: 1014-1023.
    Direct Link  |  

  72. Zhan, P., X. Liu, Z. Li, Z. Fang and Z. Li et al., 2009. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg. Med. Chem., 17: 5920-5927.
    CrossRef  |  

  73. Zhan, P., X. Liu, Z. Li, C. Pannecouque and E. De Clercq, 2009. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem., 16: 3903-3917.
    Direct Link  |  

  74. Zhan, P., X. Liu, Z. Fang, Z. Li, C. Pannecouque and E. De Clercq, 2009. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem., 44: 4648-4653.
    CrossRef  |  Direct Link  |  

  75. Zhan, P., X. Liu, Z. Fang, C. Pannecouque and E. De Clercq, 2009. 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorg Med Chem., 17: 6374-6379.
    CrossRef  |  

  76. Zhan, P., X. Liu, J. Zhu, Z. Fang, Z. Li, C. Pannecouque and E. De Clercq, 2009. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 17: 5775-5781.
    CrossRef  |  

  77. Zhan, P., X. Liu and Z. Li, 2009. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Curr. Med. Chem., 16: 2876-2889.
    Direct Link  |  

  78. Zhan, P. and X. Liu, 2009. Designed multiple ligands: An emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des., 36: 1893-1917.
    Direct Link  |  

  79. Yu, M., X. Liu, Z. Li, S. Liu, C. Pannecouque and E. De Clercq, 2009. Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonyl methylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 17: 7749-7754.
    CrossRef  |  Direct Link  |  

  80. Yu, M., X. Liu and E. De Clercq, 2009. NF-κB: The inducible factors of HIV-1 transcription and their inhibitors. Mini-Reviews Med. Chem., 9: 60-69.
    Direct Link  |  

  81. Wang, Y., X.Y. Liu and E. De Clercq, 2009. Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof. Mini-Reviews Med. Chem., 9: 379-385.
    Direct Link  |  

  82. Liu, X., P. Zhan, R. Yan, Y. Lin, J. Li, C. Pannecouque and E. De Clercq, 2009. Design, synthesis and antiviral evaluation of novel heterocyclic compounds as HIV-1 NNRTIs. Drug Discov. Ther., 2: 25-28.

  83. Liu, X., P. Zhan, C. Pannecouque and E. De Clercq, 2009. Design, synthesis and anti-HIV-1 evaluation of novel arylazolylthioacetanilides as potent NNRTIS. Antiviral Res., 82: A44-A45.

  84. Cheng, X.C., X.Y. Liu, W.F. Xu, X.L. Guo N. Zhang and Y. Song, 2009. Ligustrazine derivatives part 31: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents. Bioorg. Med. Chem., 17: 3018-3024.

  85. Cao, Y., X. Liu and E. De Clercq, 2009. Cessation of HIV-1 transcription by inhibiting regulatory protein rev-mediated RNA transport. Curr. HIV Res., 7: 101-108.
    Direct Link  |  

  86. Zhan, P., X. Liu, Y. Cao, Y. Wang, C. Pannecouque and E. De Clercq, 2008. 1,2,3-thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 18: 5368-5371.
    CrossRef  |  

  87. Zhan, P., X. Liu and E. De Clercq, 2008. Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives. Curr. Med. Chem., 15: 1529-1540.
    Direct Link  |  

  88. Yu, F., X. Liu, P. Zhan and E. De Clercq, 2008. Recent advances in the research of HIV-1 RNase H inhibitors. Mini-Rev. Med. Chem., 8: 1243-1251.
    Direct Link  |  

  89. Liu, X., R.Z. Yan, Y. Wang, P. Zhan and C. Pannecouque et al., 2008. Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-Methyl-1,1,3-trioxo-2H,4H-Pyrazolo[4,5-e] [1,2,4]thiadiazines. Arch. Pharm. Res., 341: 216-222.

  90. Lin, Y., X. Liu, R. Yan, J. Li, C. Pannecouque, M. Witvrouw and E. De Clercq, 2008. Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs). Bioorg. Med. Chem., 16: 157-163.
    Direct Link  |  

  91. Wu, J., X. Liu, X. Cheng, Y. Cao and D. Wang et al., 2007. Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 12: 2003-2016.

  92. Liu, X.Y., R.Z. Yan, N.G. Chen and W.F. Xu., 2007. Regioselective Synthesis and Anti-HIV Activity of the Novel 2- and 4-Substituted Pyrazolo[4,5-e][1,2,4]thiadiazines. Chin. Chem. Lett., 18: 137-140.

  93. Cheng, X.C., X.Y. Liu, W. F. Xu, X.L. Guo and Y. Ou, 2007. Design, synthesis and biological activities of novel Ligustrazine derivatives. Bioorg. Med. Chem., 15: 3315-3320.
    CrossRef  |  PubMed  |  

  94. Yan, R.Z., X.Y. Liu, W.F. Xu, C. Pannecouque, M. Witvrouw and E. De Clercq, 2006. Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4,5-e][1, 2, 4]thiadiazines. Arch. Pharm. Res., 29: 957-962.
    PubMed  |  

  95. Liu, X., N. Chen, R. Yan, W. Xu, M.T. Molina and S. Vega, 2006. Regioselective Synthesis of the Novel N4-Substituted Pyrazolo[4,5-e][1,2,4] thiadiazines as Potent HIV-1 NNRTIs. Heterocycles, 68: 1225-1232.

  96. Liu, X., R. Yan, N. Chen, W. Xu, M.T. Molina and S. Vega, 2006. Regioselective Synthesis of Novel N2- and N4-Substituted 7-Methylpyrazolo [4,5-e] [1,2,4]thiadiazines. Molecules, 11: 827-836.
    Direct Link  |  

  97. Cheng, X.C., X.Y.Liu and W.F. Xu, 2006. The preparation of novel ligustrazine derivatives as potential cerebrocardiac vascular agents. J. Chem. Res., 2006: 577-579.
    Direct Link  |  

  98. Cheng, X., X. Liu and W. Xu, 2006. Synthesis of novel ligustrazine derivatives as potential platelet aggregation inhibitors. Chinese Chem. Lett., 17: 1317-1320.

  99. Cheng, X., X. Liu and W. Xu, 2005. Recent advances in the structural modification of ligustrazine; cerebro- and cardiovascular activity of ligustrazine derivatives. D. Future, Vol. 30. 10.1358/dof.2005.030.10.927377.
    CrossRef  |  Direct Link  |  

  100. Shan, Z.B., M.B. Chen, X.C. Dong and X.Y. Liu, 2003. q2 guided conformation selection approach of CoM FA for HIV-1 RT inhibitors. Acta Chem. Sinica, 6: 1121-1128.

  101. Liu, X.Y., W.F. Xu and J.D. Wu, 2003. Synthesis of 4-amino-5-furyl-2-yl-4h-1, 2, 4-triazole-3-thiol derivatives as a novel class of endothelin(et) receptor antagonists. Chin Chem. Lett., 14: 790-793.

  102. Liu, X., Z. Rui and W. Xu, 2003. Synthesis of the novel liqustrazine derivatives and their protective effect on injured vascular endothelial cell damaged by hydrogen peroxide. Bioorg. Med. Chem. Lett., 13: 2123-2126.
    CrossRef  |  PubMed  |